Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRB1ADRB2ADRB3CYP11B1DPP4FGFR1FGFR2FGFR3FGFR4HRH1JAK1JAK2JAK3KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITNAOPRD1OPRK1OPRM1PPDGFRBPIK3CDSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASMOTYK2polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Farnesol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.80 |
| ▸ | MAPT | P10636 | 2/20 | 0.80 |
| ▸ | MEN1 | O00255 | 2/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.80 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.80 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.80 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.61 |
| ▸ | SQLE | Q14534 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Farnesol SCHEMBL15808561 | 1.00 | KMT2A (0.80) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| Geranylgeraniol SCHEMBL27495793 | 1.00 | KMT2A (0.80) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| Geraniol SCHEMBL20481327 | 0.98 | KMT2A (0.79) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| Geraniol SCHEMBL20481326 | 0.98 | KMT2A (0.79) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| Geraniol SCHEMBL27699074 | 0.98 | KMT2A (0.79) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| Squalene SCHEMBL27769242 | 0.90 | KMT2A (0.77) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| Squalene SCHEMBL27745351 | 0.90 | KMT2A (0.77) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| Squalene SCHEMBL27745343 | 0.90 | KMT2A (0.77) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| Squalene SCHEMBL28409601 | 0.90 | KMT2A (0.77) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| Geranylgeraniol SCHEMBL23814969 | 0.89 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021042057-A1 | SYSTEMS AND METHODS FOR PREPARING CANNABINOIDS AND DERIVATIVES | LYGOS, INC. (US) | 2021-03-04 | — | — | WO | disclosed |
| US-8324378-B2 | Prodrugs and conjugates of prenylation inhibitors | PURDUE RESEARCH FOUNDATION (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100249072-A1 | PRODRUGS AND CONJUGATES OF PRENYLATION INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2010-09-30 | — | — | US | disclosed |
| WO-2009029849-A1 | PRODRUGS AND CONJUGATES OF PRENYLATION INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2009-03-05 | — | — | WO | disclosed |
| WO-2006099313-A2 | PHOSPHATE CONJUGATES OF PRENYLATION INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249072-A1 | PRODRUGS AND CONJUGATES OF PRENYLATION INHIBITORS | FNTA, FNTB, FDPS | KMT2A 3732/4885MAPT 3584/4885MEN1 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.